Ascletis
Sustainability Report and Carbon Intensity Rankings
Is Ascletis doing their part?
Their DitchCarbon score is 42
Ascletis has a DitchCarbon Score of 42 out of 100, indicating moderate performance in sustainability. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to lower carbon intensity would enhance Ascletis’s sustainability profile.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Ascletis is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
Ascletis, located in China, operates in a region with a specific carbon intensity rating. The sustainability of the company’s operations is influenced by China’s overall carbon intensity, affecting its environmental impact.
Unlock 30+ emissions data points on Ascletis
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Ascletis
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
0.71%
...this company is doing 0.71% better in emissions than the industry average.
Ascletis, founded in 2011 and based in Chapel Hill, operates within the industrial manufacturing sector, focusing on the development of specialty therapeutics. The company is a joint venture between U.S. and Chinese entrepreneurs, targeting the discovery and development of new treatments for cancer and infectious diseases. Ascletis aims to serve the Chinese pharmaceutical market through in-licensing, clinical development, and commercialization of medicines, while also investing in the discovery of novel therapeutics for global markets.
emission intelligence's platform recommendations for Ascletis
Ascletis could reduce its emissions by approximately 30% by shifting to renewable energy sources for all its purchased electricity, heat, steam, and cooling needs.
Bad news, Ascletis hasn't committed to SBTi goals yet
Ascletis has not established specific commitments with the Science Based Targets initiative (SBTi). This means the company has yet to define or announce clear goals for reducing its greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.